Clinical Trial ProgressThe Phase 3 HAELO study completed screening and is no longer recruiting, indicating strong physician/patient interest.
EfficacyAll patients are currently attack-free and long-term prophylaxis-free for a median of 23 months, highlighting the treatment's effectiveness.
Safety ProfileSafety remains clean with no treatment-emergent serious adverse events, supporting Lonvo-z’s best-in-class efficacy profile.